SMHGF
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its princi… Read more
SMHGF (SMHGF) - Net Assets
Latest net assets as of June 2025: $7.23 Billion USD
Based on the latest financial reports, SMHGF (SMHGF) has net assets worth $7.23 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.60 Billion) and total liabilities ($5.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.23 Billion |
| % of Total Assets | 57.39% |
| Annual Growth Rate | 7.28% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9.08 |
SMHGF - Net Assets Trend (2020–2024)
This chart illustrates how SMHGF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SMHGF (2020–2024)
The table below shows the annual net assets of SMHGF from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.07 Billion | -2.14% |
| 2023-12-31 | $7.22 Billion | +1.05% |
| 2022-12-31 | $7.15 Billion | +10.60% |
| 2021-12-31 | $6.46 Billion | +21.12% |
| 2020-12-31 | $5.34 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SMHGF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $7.07 Billion | 100.00% |
| Total Equity | $7.07 Billion | 100.00% |
SMHGF Competitors by Market Cap
The table below lists competitors of SMHGF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hefei Chipmore Technology Co. Ltd. A
SHG:688352
|
$534.02 Million |
|
COHTF
PINK:COHTF
|
$534.23 Million |
|
SZZT Electronics Co Ltd
SHE:002197
|
$534.28 Million |
|
Jinxi Axle Co Ltd
SHG:600495
|
$534.28 Million |
|
Mersen SA
PA:MRN
|
$533.96 Million |
|
Metallus, Inc
NYSE:MTUS
|
$533.89 Million |
|
Kelington Group Bhd
KLSE:0151
|
$533.88 Million |
|
Aucma Co Ltd
SHG:600336
|
$533.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SMHGF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,222,736,000 to 7,068,115,000, a change of -154,621,000 (-2.1%).
- Net income of 733,165,000 contributed positively to equity growth.
- Dividend payments of 401,484,000 reduced retained earnings.
- Share repurchases of 687,985,000 reduced equity.
- Other factors increased equity by 201,683,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $733.16 Million | +10.37% |
| Dividends Paid | $401.48 Million | -5.68% |
| Share Repurchases | $687.99 Million | -9.73% |
| Other Changes | $201.68 Million | +2.85% |
| Total Change | $- | -2.14% |
Book Value vs Market Value Analysis
This analysis compares SMHGF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $2.03 | $0.69 | x |
| 2021-12-31 | $2.45 | $0.69 | x |
| 2022-12-31 | $2.68 | $0.69 | x |
| 2023-12-31 | $2.76 | $0.69 | x |
| 2024-12-31 | $2.80 | $0.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SMHGF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.37%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.05%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.63x
- Recent ROE (10.37%) is below the historical average (13.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 12.63% | 14.85% | 0.41x | 2.06x | $139.36 Million |
| 2021 | 23.41% | 30.14% | 0.49x | 1.58x | $863.40 Million |
| 2022 | 13.05% | 14.72% | 0.59x | 1.51x | $217.70 Million |
| 2023 | 9.90% | 10.82% | 0.61x | 1.50x | $-7.51 Million |
| 2024 | 10.37% | 11.05% | 0.58x | 1.63x | $26.35 Million |
Industry Comparison
This section compares SMHGF's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SMHGF (SMHGF) | $7.23 Billion | 12.63% | 0.74x | $533.97 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |